| 1 |
van Velzen HG, Schinkel AFL, Baart SJ, et al. Outcomes of contemporary family screening in hypertrophic cardiomyopathy[J] .Circ Genom Precis Med, 2018, 11(4): e001896.
|
| 2 |
Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12): 1249-1254.
|
| 3 |
赵丹, 刘丽文, 纳丽莎, 等. 三维斑点追踪技术评价家族性肥厚型心肌病MYBPC3基因突变携带者左心室功能的早期改变[J]. 中国超声医学杂志, 2017, 33(9): 783-786.
|
| 4 |
Velicki L, Jakovljevic DG, Preveden A, et al. Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy[J]. BMC Cardiovasc Disord, 2020, 20(1): 516.
|
| 5 |
Garfinkel AC, Seidman JG, Seidman CE. Genetic pathogenesis of hypertrophic and dilated cardiomyopathy[J]. Heart Failure Clinics, 2018, 14(2):139-146.
|
| 6 |
Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw rozpoznawania i postepowania w kardiomiopatii przerostowej, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy[J]. Kardiol Pol, 2014, 72(11): 1054-1126.
|
| 7 |
Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing[J]. Circulation, 2013, 127(1): 48-54.
|
| 8 |
Page SP, Kounas S, Syrris P, et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome[J]. Circ Cardiovasc Genet, 2012, 5(2): 156-166.
|
| 9 |
Michels M, Soliman OI, Phefferkorn J, et al. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers[J]. Eur Heart J, 2009, 30(21): 2593-2598.
|
| 10 |
Girolami F, Ho CY, Semsarian C, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations[J]. J Am Coll Cardiol, 2010, 55(14): 1444-1453.
|
| 11 |
宋雷, 邹玉宝, 汪道文, 等. 中国成人肥厚型心肌病诊断与治疗指南[J].中华心血管病杂志, 2017, 45(12): 1015-1032.
|
| 12 |
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Thorac Cardiovasc Surg, 2021, 162(1): e23-e106.
|
| 13 |
Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy[J]. Eur Heart J, 2010, 31(13): 1551-1553.
|
| 14 |
Page SP, Kounas S, Syrris P, et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome[J]. Circ Cardiovasc Genet, 2012, 5(2): 156-166.
|
| 15 |
Jensen MK, Havndrup O, Christiansen M, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: a 12-year follow-up study of clinical screening and predictive genetic testing[J]. Circulation, 2013, 127(1): 48-54.
|
| 16 |
Lakdawala NK, Thune JJ, Maron BJ, et al. Electrocardiographic features of sarcomere mutation carriers with and without clinically overt hypertrophic cardiomyopathy[J]. Am J Cardiol, 2011, 108(11): 1606-1613.
|
| 17 |
张娟, 刘丽文, 朱晓丽, 等. 心电图对家族性肥厚型心肌病肌小节突变基因携带者早期诊断的价值[J]. 实用心电学杂志, 2018, 27(6): 386-391.
|
| 18 |
Jalanko M, Helio T, Mustonen P, et al. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations[J]. J Electrocardiol, 2018, 51(6): 983-989.
|
| 19 |
Osterberg AW, Ostman-Smith I, Jablonowski R, et al. High ECG risk-scores predict late gadolinium enhancement on magnetic resonance imaging in HCM in the young[J]. Pediatr Cardiol, 2021, 42(3): 492-500.
|
| 20 |
Nagueh SF, Bachinski LL, Meyer D, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy[J]. Circulation, 2001, 104(2): 128-130.
|
| 21 |
Nagueh SF, McFalls J, Meyer D, et al. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease[J]. Circulation, 2003, 108(4): 395-398.
|
| 22 |
Michels M, Soliman OI, Kofflard MJ, et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in dutch myosin-binding protein C founder mutations[J]. JACC: Cardiovascular Imaging, 2009, 2(1): 58-64.
|
| 23 |
Gandjbakhch E, Gackowski A, Tezenas Du Montcel S, et al. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging[J]. Eur Heart J, 2010, 31(13): 1599-1607.
|
| 24 |
Peyrou J, Réant P, Reynaud A, et al. Morphological and functional abnormalities pattern in hypertrophy-free HCM mutation carriers detected with echocardiography[J]. Int J Cardiovasc Imaging, 2016, 32(9): 1379-1389.
|
| 25 |
Ho CY, Sweitzer NK, McDonough B, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy[J]. Circulation, 2002, 105(25): 2992-2997.
|
| 26 |
Zhao B, Wang S, Chen J, et al. Echocardiographic characterization of hypertrophic cardiomyopathy in Chinese patients with myosin-binding protein C3 mutations[J]. Exp Ther Med, 2017, 13(3): 995-1002.
|
| 27 |
Kauer F, van Dalen BM, Michels M, et al. Delayed and decreased LV untwist and unstrain rate in mutation carriers for hypertrophic cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2017, 18(4): 383-389.
|
| 28 |
赵丹, 刘丽文, 纳丽莎, 等. 三维斑点追踪技术评价家族性肥厚型心肌病MYBPC3基因突变携带者左心室功能的早期改变[J].中国超声医学杂志, 2017, 33(9): 783-786.
|
| 29 |
van Velzen HG, Schinkel A, van Grootel R, et al. Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes[J]. Neth Heart J, 2019, 27(3): 117-126.
|
| 30 |
Santambrogio GM, Maloberti A, Vallerio P, et al. Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?[J]. Int J Cardiovasc Imaging, 2019, 35(12): 2167-2175.
|
| 31 |
Baudry G, Nicolas M, Reynaud A, et al. Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations[J].Eur Heart J Cardiovasc Imaging, 2020, 21(3): 291-298.
|
| 32 |
Gruner C, Chan RH, Crean A, et al. Significance of left ventricular apical-basal muscle bundle identified by cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy[J]. Eur Heart J, 2014, 35(39): 2706-2713.
|
| 33 |
Captur G, Lopes LR, Patel V, et al. Abnormal cardiac formation in hypertrophic cardiomyopathy: fractal analysis of trabeculae and preclinical gene expression[J]. Circ Cardiovasc Genet, 2014, 7(3): 241-248.
|
| 34 |
Reant P, Captur G, Mirabel M, et al. Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy[J]. J Cardiovasc Magn Reson, 2015, 17(1): 64.
|
| 35 |
Maron MS, Olivotto I, Harrigan C, et al. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy[J]. Circulation, 2011, 124(1): 40-47.
|
| 36 |
Deva DP, Williams LK, Care M, et al. Deep basal inferoseptal crypts occur more commonly in patients with hypertrophic cardiomyopathy due to disease-causing myofilament mutations[J]. Radiology, 2013, 269(1): 68-76.
|
| 37 |
Tarkiainen M, Sipola P, Jalanko M, et al. CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation[J]. Sci Rep, 2019, 9(1): 5960.
|
| 38 |
Hughes RK, Camaioni C, Augusto JB, et al. Myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers[J]. J Am Heart Assoc, 2021, 10(15): e020227.
|
| 39 |
Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy[J]. N Engl J Med, 2010, 363(6): 552-563.
|
| 40 |
Ho CY, Day SM, Colan SD, et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: findings from the HCMNet study[J]. JAMA Cardiol, 2017, 2(4): 419-428.
|
| 41 |
Silva D, Madeira H, Almeida A, et al. Tissue Doppler imaging and plasma N-terminal probrain natriuretic peptide for the identification of hypertrophic cardiomyopathy mutation carriers[J]. Am J Cardiol, 2013, 112(7): 996-1004.
|
| 42 |
Ho JE, Shi L, Day SM, et al. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy[J] .Open Heart, 2017, 4(2): e000615.
|
| 43 |
Adalsteinsdottir B, Burke M, Maron BJ, et al. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers[J]. Open Heart, 2020, 7(1): e001220.
|